Surgical Management of Low-Risk Papillary Thyroid Cancer
Current medical literature clearly defines a group of low-risk papillary thyroid carcinomas that may be treated effectively with thyroid lobectomy alone. Considerations regarding overall survival, local control, and perioperative morbidity in addition to patient monitoring, disease features, and patient preference, guide the treatment team in the extent of surgical intervention. The effectiveness of thyroid lobectomy for papillary thyroid carcinoma is dependent upon accurate preoperative and intraoperative exclusion of bilateral disease, extrathyroidal extension, or nodal metastasis. The advantages over total thyroidectomy are reduced perioperative morbidity and less dependence upon thyroid hormone replacement. The disadvantages are more dependence upon ultrasound surveillance, inability to use radioiodine, and potential need for completion thyroidectomy.
KeywordsLow risk Papillary thyroid carcinoma Total thyroidectomy Thyroid lobectomy Hemithyroidectomy Thyroid cancer Surgery
- 8.Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.Google Scholar
- 10.Leiker AJ, Yen TW, Cheung K, Evans DB, Wang TS. Cost analysis of thyroid lobectomy and intraoperative frozen section versus total thyroidectomy in patients with a cytologic diagnosis of “suspicious for papillary thyroid cancer”. Surgery. 2013;154:1307–13; discussion 1313–4.CrossRefPubMedGoogle Scholar
- 17.Vaisman F, Shaha A, Fish S, Michael Tuttle R. Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer. Clin Endocrinol (Oxf). 2011;75:112–9.CrossRefGoogle Scholar
- 18.Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA, editors. SEER Cancer Statistics Review, 1975–2012, National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/csr/1975_2012/, based on November 2014 SEER data submission, posted to the SEER web site, April 2015.
- 19.Kiernan CM, Parikh AA, Parks LL, etal. Use of Radioiodine after Thyroid Lobectomy in patients with differentiates Thyroid Cancer. Does it change outcome? J Am Coll Surg. 04/2015;220(4).Google Scholar